EPISODE-III Trial Results – presented at the 2026 ASCO Annual Meeting
At the 2026 ASCO, the EPISODE-III Trial team presented the results of the trial that was conducted at 36 institutions in Japan with a total 882 enrolled participants. The study aimed to evaluate whether low-dose aspirin improves disease-free survival (DFS) in unselected stage III CRC receiving standard adjuvant chemotherapy.
Visit the ASCO Abstract article with the details presented.
Contact Details
If you are an individual who is interested in taking part in Add-Aspirin, please talk to your doctor who will be able to consider whether you are suitable for the trial.
For healthcare professionals
Please log into the members area for Add-Aspirin contact details.
Register Interest
For healthcare professionals
If your centre would like to recruit participants to Add-Aspirin, contact us:
mrcctu.add-aspirin@ucl.ac.uk
From Monday 16th March 2020, to RANDOMISE a participant in the UK please call +44 (0)20 7670 4925, rather than the usual randomisation line.
To RANDOMISE a participant from Republic of Ireland or India only, please use the 'Register a participant' link above to randomise online. Please make sure to press 'Randomise' once logged in to the server.
Unblind a participant in the UK